Loading...
•
Jun 30, 2025
Dynavax Q2 2025 Earnings Report
Dynavax reported its financial results for the second quarter of 2025, highlighting record HEPLISAV-B net product revenue and progress in its vaccine pipeline.
Key Takeaways
Dynavax delivered robust Q2 2025 results, achieving record quarterly net product revenue for HEPLISAV-B of $91.9 million, a 31% increase year-over-year. The company reported a GAAP net income of $18.7 million and an EPS of $0.14 diluted. HEPLISAV-B's U.S. market share increased to approximately 45%.
Record HEPLISAV-B quarterly net product revenue of $91.9 million, up 31% year-over-year.
HEPLISAV-B's U.S. market share increased to approximately 45% in Q2 2025.
GAAP net income of $18.7 million and diluted EPS of $0.14 for the quarter.
Refined full-year 2025 HEPLISAV-B net product revenue guidance to $315 million to $325 million.
Revenue by Segment
Forward Guidance
Dynavax refined its full-year 2025 HEPLISAV-B net product revenue guidance and expects continued progress in its clinical pipeline.
Positive Outlook
- Refined full year 2025 HEPLISAV-B net product revenue guidance range to $315 million to $325 million, an increase from the prior range.
- Top-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in August 2025.
- Completed dosing in Part 1 of Phase 1/2 trial of pandemic influenza adjuvant program.
- Plague vaccine program Phase 2 clinical trial expected to initiate in the second half of 2025.
- Lyme disease vaccine candidate plans to initiate clinical development in 2027.
Challenges Ahead
- No specific negative forward guidance points were highlighted in the report.
- The company did not provide specific negative forward guidance points.
- No explicit negative forward guidance was mentioned.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...